01 Which cancers benefit most from NGS testing?
Clinicians
NCCN guidelines strongly recommend broad-panel Next-Generation Sequencing (NGS) to identify actionable genomic alterations in advanced, metastatic, or high-risk cancers, particularly for NSCLC, breast, and gastrointestinal tumors
No results found!